{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:24:31Z","timestamp":1768868671045,"version":"3.49.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Gout is associated with the risk of cardiovascular morbidity and mortality, but the biological relationship between the two remains uncertain. The demonstration of reduction of cardiovascular risk with appropriate gout treatment would argue for a causal role for gout in cardiovascular disease. We reviewed recent studies that address the relationship between gout and cardiovascular disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Studies are conflicting; some show that lowering serum uric acid levels leads to better cardiovascular outcomes, whereas others show no such benefit. Inconsistencies in study design may contribute to these variations in outcome. Additionally, different gout treatment strategies may affect cardiovascular outcomes differently.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Despite an abundance of data generated in the last 5 years, it remains unclear whether treating gout with urate-lowering therapy provides a cardiovascular benefit. Additionally, further studies are needed to clarify whether different urate-lowering drugs confer different cardiovascular risks or benefits. Nonurate-lowering agents used for gout or commonly used in gout patients, such as colchicine and statins, may also improve cardiovascular outcomes in this population.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000585","type":"journal-article","created":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T07:43:36Z","timestamp":1546242216000},"page":"118-124","source":"Crossref","is-referenced-by-count":39,"title":["Gout and cardiovascular disease: crystallized confusion"],"prefix":"10.1097","volume":"31","author":[{"given":"Aryeh M.","family":"Abeles","sequence":"first","affiliation":[{"name":"Division of Rheumatology, University of Connecticut Health Center, Meriden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Pillinger","sequence":"additional","affiliation":[{"name":"Crystal Diseases Study Group, Division of Rheumatology, New York University School of Medicine, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007\u20132008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"(Suppl 10)","key":"R2-20230829","article-title":"Contemporary Prevalence of Gout and Hyperuricemia in the United States (National Health and Nutrition Examination Survey [NHANES] 2015\u20132016) and Decadal Trends (NHANES 2007\u20132016) [abstract]","volume":"70","author":"Chen-Xu","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R3-20230829","first-page":"301","article-title":"Trends in hyperuricemia and gout prevalence: nutrition and health survey in Taiwan from 1993\u20131996 to 2005\u20132008","volume":"20","author":"Chuang","year":"2011","journal-title":"Asia Pac J Clin Nutr"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","article-title":"Prevalence of contraindications and prescription of pharmacologic therapies for gout","volume":"124","author":"Keenan","year":"2011","journal-title":"Am J Med"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/annrheumdis-2016-210588","article-title":"The unclosing premature mortality gap in gout: a general population-based study","volume":"76","author":"Fisher","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/ard.2011.200523","article-title":"Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study","volume":"71","author":"Teng","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","article-title":"Independent impact of gout on mortality and risk for coronary heart disease","volume":"116","author":"Choi","year":"2007","journal-title":"Circulation"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archinte.168.10.1104","article-title":"Long-term cardiovascular mortality among middle-aged men with gout","volume":"168","author":"Krishnan","year":"2008","journal-title":"Arch Intern Med"},{"key":"R9-20230829","article-title":"Association between gout and cardiovascular risk: a nation-wide case-control study","author":"Liang","year":"2018","journal-title":"Joint Bone Spine"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13075-018-1606-z","article-title":"Gout and the risk of myocardial infarction in older adults: a study of Medicare recipients","volume":"20","author":"Singh","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3899\/jrheum.170555","article-title":"Crystal-proven gout and characteristic gout severity factors are associated with cardiovascular disease","volume":"45","author":"Disveld","year":"2018","journal-title":"J Rheumatol"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1136\/annrheumdis-2016-210357","article-title":"Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment","volume":"76","author":"Andr\u00e9s","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/annrheumdis-2012-202972","article-title":"Impact of allopurinol on risk of myocardial infarction","volume":"74","author":"Grimaldi-Bensouda","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"e99102","DOI":"10.1371\/journal.pone.0099102","article-title":"Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study","volume":"9","author":"Kok","year":"2014","journal-title":"PLoS One"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/art.40486","article-title":"Allopurinol dose escalation and mortality among patients with gout: a national propensity-matched cohort study","volume":"70","author":"Coburn","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1136\/heartjnl-2014-306670","article-title":"Allopurinol use and risk of nonfatal acute myocardial infarction","volume":"101","author":"de Abajo","year":"2015","journal-title":"Heart"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijcard.2017.02.013","article-title":"Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: a population-based study","volume":"233","author":"Lin","year":"2017","journal-title":"Int J Cardiol"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"e0146172","DOI":"10.1371\/journal.pone.0146172","article-title":"Impact of urate level on cardiovascular risk in allopurinol treated patients. A nested case-control study","volume":"11","author":"S\u00f8ltoft Larsen","year":"2016","journal-title":"PLoS One"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"e0193622","DOI":"10.1371\/journal.pone.0193622","article-title":"An evaluation of longitudinal changes in serum uric acid levels and associated risk of cardio-metabolic events and renal function decline in gout","volume":"13","author":"Desai","year":"2018","journal-title":"PLoS One"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"299.e2","DOI":"10.1016\/j.amjmed.2015.11.003","article-title":"Effect of allopurinol on cardiovascular outcomes in hyperuricemic patients: a cohort study","volume":"129","author":"Larsen","year":"2016","journal-title":"Am J Med"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.3899\/jrheum.141542","article-title":"Effect of urate-lowering therapy on the risk of cardiovascular disease and all-cause mortality in patients with gout: a case-matched cohort study","volume":"42","author":"Chen","year":"2015","journal-title":"J Rheumatol"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"653.e7","DOI":"10.1016\/j.amjmed.2015.01.013","article-title":"Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study","volume":"128","author":"Kim","year":"2015","journal-title":"Am J Med"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/rheumatology\/kex065","article-title":"Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis","volume":"56","author":"Zhang","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12872-018-0757-9","article-title":"Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Bredemeier","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"e013774","DOI":"10.1136\/bmjopen-2016-013774","article-title":"Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study","volume":"6","author":"Mackenzie","year":"2016","journal-title":"BMJ Open"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jacc.2017.12.052","article-title":"Cardiovascular risks of probenecid versus allopurinol in older patients with gout","volume":"71","author":"Kim","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.118.033992","article-title":"Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol: a population-based cohort study","volume":"138","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"R29-20230829","first-page":"393","article-title":"Major cardiovascular events in patients with gout and associated cardiovascular disease or heart failure and chronic kidney disease initiating a xanthine oxidase inhibitor","volume":"10","author":"Foody","year":"2017","journal-title":"Am Health Drug Benefits"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"e005354","DOI":"10.1136\/bmjopen-2014-005354","article-title":"Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia","volume":"4","author":"MacDonald","year":"2014","journal-title":"BMJ Open"},{"key":"R31-20230829","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1136\/annrheumdis-2015-207984","article-title":"Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims","volume":"75","author":"Solomon","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1136\/annrheumdis-2015-207984","article-title":"Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims","volume":"75","author":"Solomon","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"(Suppl 65)","key":"R33-20230829","first-page":"156","article-title":"Colchicine and the risk of acute cardiovascular (CV) events among gout patients: the New York Department of Veterans Affairs retrospective cohort study","volume":"66","author":"Crittenden","year":"2014","journal-title":"Arthritis Rheumatism"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R35-20230829","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Anti-inflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"(Suppl 1)","key":"R36-20230829","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/kex453","article-title":"Update on colchicine, 2017","volume":"57","author":"Slobodnick","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/art.21521","article-title":"Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy?","volume":"54","author":"Abeles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R38-20230829","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2018.03.007","article-title":"Statin use and mortality in gout: a general population-based cohort study","author":"Keller","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R39-20230829","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201903000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T06:52:34Z","timestamp":1693291954000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201903000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000585","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}